REFRACTORY HURTHLE CELL THYROID CANCER

Clinical trials for REFRACTORY HURTHLE CELL THYROID CANCER explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY HURTHLE CELL THYROID CANCER trials appear

Sign up with your email to follow new studies for REFRACTORY HURTHLE CELL THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Scientists test drug duo to stall tough thyroid cancer

Disease control Ongoing

This study is testing if combining two drugs, sorafenib and everolimus, works better than sorafenib alone to control a rare, aggressive form of thyroid cancer that no longer responds to standard radioactive iodine treatment. The trial will enroll about 35 adults to see if the dru…

Matched conditions: REFRACTORY HURTHLE CELL THYROID CANCER

Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control

Last updated Mar 24, 2026 12:02 UTC

REFRACTORY HURTHLE CELL THYROID CANCER

Get alerted when new REFRACTORY HURTHLE CELL THYROID CANCER trials appear

Scientists test drug duo to stall tough thyroid cancer